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Abstract
Background: Generic drug policies are often associated with concerns about the quality and effectiveness of these
products. Phase IV clinical trials may be a suitable design to assess the effectiveness and safety of generic drugs.
The objective of this study was to describe the effectiveness and the safety of the generic abacavir/lamivudine and
efavirenz in treatment-naïve HIV-infected patients.
Methods: A monocentric, nonrandomized, open-label, phase IV study in treatment naïve HIV-infected patients
18 years or older with indication to receive abacavir/lamivudine and efavirenz were recruited from a program that
provides comprehensive outpatient consultation and continuing care. The primary end-point was to achieve viral load
<40 copies/mL at 12 months after baseline to assess effectiveness. Secondary end-point of the study were 1) to asses
increasing in T-CD4 lymphocytes levels as accompaniment to asses effectiveness, and 2) to assess both gastrointestinal,
skin, and central nervous system symptoms, and lipid profile, cardiovascular risk, renal, and hepatic function as safety
profile. Data were determined at baseline, 3, 6, and 12 months. Close clinical monitoring and pharmaceutical care were
used for data collection. Wilcoxon matched-pairs signed-rank test was used to compare proportions or medians.
Results: Sixty patients were invited to participate in the study; 42 were enrolled and 33 completed the follow-up. Of
the nine patients excluded from the study, only one was withdrawn due to adverse events. At 12 months, 31 of 42
patients (73.8 % in intention-to-treat analysis) achieved a viral load of HIV1 RNA <40 copies/mL. There was a significant
increase (172 cells/mm3) in the median for CD4 T lymphocyte count. The adverse events were mild and met the safety
profile for this antiretroviral regimen, mainly of central nervous system symptoms, skin rash, lipid abnormalities, and an
increase of 2 % in the median of the percentage of cardiovascular risk.
Conclusions: The clinical outcomes of generic version of abacavir/lamivudine and efavirenz in HIV treatment naïve
patients showed the expected safety and effectiveness profile of proprietary ARV drugs.
Trial registration: Registro Público Cubano de Ensayos Clínicos (RPCEC) ID: RPCEC00000202. Registered 19 November
2015.
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Background
Substantial progress has been made in the prevention and
treatment of HIV/AIDS but it remains a public health
challenge. A report on the global AIDS epidemic 2013
informed that in 2012 there were 35.3 million people
living with HIV, 2.3 million new infections, and 1.6
million AIDS-related deaths [1]. It is well known that
people with HIV/AIDS need comprehensive care, including
the use of antiretroviral therapy (ART) which extends the
lives of HIV patients and reduces the possibility of infecting
other people [2]. Therefore, availability and access to safe
and effective antiretroviral (ARV) drugs are important
requirements for appropriate medical care for this group
of patients [3].
The evidence-based clinical guidelines for treating
HIV/AIDS infection in Colombia recommended the regi-
men abacavir/lamivudine (ABC/3TC) and efavirenz (EFV)
as the preferred first line, which has been assed as a cost-
effectiveness ARV treatment in the Colombia settings [4].
In addition, although in the World Health Organization
(WHO) evidence-based clinical guidelines on the use of
ARV drugs, the preferred first line regimen is tenofovir/
lamivudine (or emtricitabine) and EFV, the scheme ABC/
3TC and EFV is an alternative for first-line regimen [5].
Both the Colombia [4] and WHO [5] guidelines stated
that in patients with pre-treatment HIV RNA >100,000
copies/mL, the regimens ABC/3TC and EFV or ABC/3TC
and atazanavir/ritonavir do not be used due to higher
rates of virologic failure.
The development and consolidation of generic drug
policy is a valid option for improving the availability of
and access to ART [6]. On average, generic ARV drugs
are sold at a cost roughly 30 % below that of original
ARV drugs [7] and generics play an important role in
price negotiation discussions with trademarked companies
[8]. In addition, generic drug policy is recognized as a key
strategy for price reduction ARV drugs a monopoly
situation. In this way, some governments, for instance
Brazil, had negotiated voluntary licenses with multinational
pharmaceutical companies to promote generic competition
and reduce prices. As consequence, in the case of atazanavir
150 mg, the cost per patient per year varied from US$
2815.07 in 2005 to US$ 1150.35 in 2013 [9].
At the same time, generic drug policy is concerned
with the quality and effectiveness of products, including
ARV drugs [10]. Relate to quality, although bioavailability
and bioequivalence studies are the typical to determine
bioequivalence of generic drugs [11], dissolution testing
and comparative studies in-vitro-in-vivo correlation are a
mean to define a direct relationship between bioavailability
of a drug and its in-vitro dissolution rate and are refereed
as an option for this goal. Thus, this kind of studies are an
important strategy to predict the in-vivo bioavailability
and in some cases substituting clinical studies to determine
bioequivalence [12]. In this way, in Colombia dissolution
testing and comparative studies in-vitro-in-vivo correlation
are considered as an alternative to clinical studies to
determine bioequivalence for some generic drugs [13].
For instance, the drugs evaluated in this study, obtained
the marketing authorization proved that there were not
differences in dissolution behavior of dosage forms
between innovators (reference products) and their
generic counterparts (tested products), on March 2010
for ABC/3TC, and November 2006 for EFV. Thus, al-
though bioequivalence of ABC/3TC and EFV generics
have been determined according to Colombia regula-
tions [13], these drugs did not have WHO prequalifica-
tion medicines, which may add concerns about quality
of these kind of products marketing in Colombia.
The results of effectiveness and safety in the clinical
practice may contribute to generate trust in the quality
of generic ARV drugs manufacturing in Colombia. There-
fore, there is the need to obtain clinical results from HIV/
AIDS patients who are on generic ART, under standardized
conditions of medical practice [14]. Nonrandomized, open-
label, phase IV studies can be designed and conducted to
achieve this goal [14, 15]. In this type of study, close clinical
monitoring and pharmaceutical care could be used to im-
prove data collection and evaluation of the results regarding
the safety and efficacy of ART [14, 16, 17]. Therefore, the
objective of the present study was to describe the ef-
fectiveness and the safety of the generic of the generic
version of ABC/3TC and EFV in treatment naïve HIV-
infected patients attending a program that provides
complete outpatient consultation and continuing care
for patients with HIV/AIDS.
Methods
Research design
The present study was monocentric, nonrandomized,
open-label, phase IV study in treatment-naïve HIV-infected
patients 18 years or older with indication to receive com-
bination antiretroviral therapy (cART) containing ABC/
3TC and EFV.
Patients and setting
Patients were recruited between January 2011 and
November 2012 from Corporacion de Lucha Contra el
Sida, Cali-Colombia, an institute that provides compre-
hensive outpatient consultation and continuing care of pa-
tients with HIV/AIDS. In Colombia, a previous study
conducted in cohorts of patients with similar conditions
showed a close to 20 % drop-out rate and a percentage of
virologic failure close to 15 %, during first year on ART
[14]. Thus, if we assumed a virologic failure rate of 15 %, a
group of 33 patients are need to find at least five failures
per treatment [18]. In addition, we estimated a withdrawal
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rate of 20 %, thus a group of 41 patients are need as a
minimum sample size for the study.
Inclusion criteria
Patient eligibility included: a) HIV diagnosed by laboratory
testing (presumptive tests and confirmatory test, CD4 T-
lymphocytes count, and viral load values); b) treatment
naïve and no less than 18 years of age; c) met immuno-
logic, virologic, or clinical criteria for starting cART, ac-
cording to recommendations of the International AIDS
Society–USA Panel of 2010 [19] regarding to abacavir/
lamivudine and efavirenz scheme, such as: i) viral load
(RNA copies) <100.000 copies/mL and regardless of CD4
cell count; ii) genotypic test negative for drug resistance,
iii) cardiovascular (CV) risk assessed as low (<10 %), using
the Framingham risk score [20] d) major histocompatibility
complex allele (HLA-B*57) genotype negative; and e) ab-
sence of metabolic syndrome, diabetes, and current or past
medical history of cardiovascular disease (CVD).
Exclusion criteria
Patients with any of the following clinical condition were
excluded: a) pregnant, lactating, or women of child-bearing
age not using a contraception method; b) current or past
medical history of renal failure (serum creatinine equivalent
to an estimated creatinine clearance <60 mL/minute) or
hepatic failure; c) serious anemia (Hb <7.0 g/dL); d) high-
sensitivity C-reactive protein (hs-CRP) >2.0 mg/L and two
of the following CV risk factors: 1) smoking, 2) total
cholesterol (TC) ≥240 mg/dL, 3) triglycerides >200 mg/dL,
4) high-density lipoprotein cholesterol (HDL-C) ≤40 mg/dL,
5) glycemia > 110 mg/dL, or 6) large waist circumference
and waist/hip ratio (men with waist circumference >102 cm
and waist/hip ratio >0.9 or women with waist circum-
ference >88 cm and waist/hip ratio >0.8); e) three of
the 6 CV risk factors cited above; f ) being treated with
drug(s) with high probability of clinically relevant interac-
tions (e.g., rifampicin, itraconazole); f ) major psychiatric
disorder; g) current or past medical history of substance
abuse; or h) limitations to attending the visits.
All enrolled patients were assigned the generic cART
regimen ABC/3TC 600/300 mg and EFV 600 mg taken
once daily [19] (provided by Humax Pharmaceutical S.A.,
Medellin-Colombia) and were followed for 12 months.
The primary end-point was to achieve viral load <40
copies/mL at 12 months after baseline to assess effect-
iveness. Secondary end-point of the study were 1) to
asses increasing in T-CD4 lymphocytes levels as accom-
paniment to asses effectiveness, and 2) to assess both
gastrointestinal, skin, and central nervous system symp-
toms, and lipid profile, cardiovascular risk, renal, and
hepatic function as safety profile.
Effectiveness and safety assessments
Serum biochemistry: transaminases, creatinine, lipids,
glucose, and hs-CRP, hematology (red and white blood
cell differential count, platelet count, hemoglobin, and
hematocrit), HIV-1 RNA viral load and CD4 lymphocytes
count as medical history and physical examination, includ-
ing measurements of waist and hip circumferences, were
inclusion criteria for screening.
HIV-1 RNA load (RNA copies/mL) and CD4 cell
count (cells/mm3) were determined at baseline, 3, 6,
and 12 months, as clinical outcomes to assess effective-
ness. In detail, effectiveness related to viral load was
defined as a viral load <40 copies/mL measured at
12 months after baseline. Viral load was quantified by
real-time reverse transcriptase PCR (RT-PCR) Abbott
Real Time HIV-1 m2000 assay (Abbott, Chicago, IL).
Blood samples were collected by a certified technician
and processed in a centralized national reference la-
boratory. PCR testing was performed on frozen samples
rather than as soon as blood was drawn.
To assess drug safety, liver tests (alanine aminotransferase
and aspartate aminotransferase), renal tests (serum
creatinine and estimated creatinine clearance, using
the Cockcroft-Gault method), complete blood count
(number of red blood cells, white blood cells, and
platelet, hemoglobin, and hematocrit), and CV risk as-
sessment, using the Framingham risk score [20], in-
cluding glucose, hs-CRP, full lipid profile, and waist
and hip circumferences were performed. Except for
lipid profile and assessment of metabolic syndrome
and CV risk, which were measured at baseline, and at
months 6 and 12, all tests were performed at baseline,
3, 6, and 12 months. Patients were asked for adverse events
at each visit. The most common adverse effects associated
with ARV drugs (gastrointestinal, skin, and central nervous
system [CNS] symptoms) were judged at each medical
examination or appointment for pharmaceutical care.
Monitoring and data collection
At each medical examination blood samples were taken
for safety assessment; complete physical and clinical
monitoring was performed by a physician trained and
experienced in the care of persons with HIV/AIDS; and
pharmaceutical care using the DADER method [21] was
performed by a pharmacist trained in this practice. All
data were recorded in the institution’s medical records.
The DADER method for pharmaceutical care is a sys-
tematic process developed by the Research Group of
Pharmaceutical Care at the University of Granada, Spain.
The intervention is based on the use of pharmacotherapy
records, evaluation of an assessment form that includes all
HIV/AIDS health problems and the drugs used to treat
these medical problems, and their assessment on a specific
date. Thus, pharmacists did the following [17, 21]:
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(a)Obtained patient data related to HIV/AIDS medical
problems and current drug therapy with special
focus on adherence to treatment and detection of
adverse events. Patient-specific data were collected
by interviewing the patient and reviewing the drug
and clinical records (mainly drug history and the
results of clinical laboratory tests). During the first
interview, 1 month’s supply of drugs for the cART
regimen were dispensed and the patient received
verbal counseling regarding cART, including the
medication schedule and possible adverse effects.
At weeks 1 and 2 and at the end of first month of
cART follow-up calls were carried out. In addition,
during the all-period of following patients may contact
to pharmacist to ask any question related to some
possible adverse event.
(b)Used the collected data to complete the assessment
form, which was interpreted and evaluated once all
the necessary information was added.
(c)Evaluated the patient’s drug therapy outcomes. The
aim of this activity was to assess whether the desired
treatment goals for HIV/AIDS were achieved. For
patients whose goals were not yet achieved, the
pharmacist developed therapeutic plans that
included interventions with the aim of achieving the
desired clinical outcome. In this way, pharmacist
asked and for adverse events at each visit. So, both
the most common adverse effects associated with
ARV drugs (gastrointestinal, skin, and central CNS
symptoms) and results of laboratory test were
judged at each appointment for pharmaceutical care.
If pharmacist identified some safety problem, he
informed to clinician the safety and the physician
valued and verified the safety problem.
(d)Conducted an intervention intended to directly
prevent or resolve any potential or actual patient
health outcomes that were not consistent with the
objectives of pharmacotherapy and were associated
with the use of medicines (negative outcomes
associated with medication [NOM]) and situations in
which the use of medicines caused or might cause the
appearance of a NOM (drug-related problems). If
necessary, lifestyle interventions to improve adherence
and/or use of drug therapy were implemented.
(e)Completed a new assessment form. Completion of
an intervention should have generated a change in
the patient’s assessment. Depending on whether a
NOM still existed, the therapeutic plan was
completed.
ARV drugs were dispensed monthly and patient drug
adherence was assessed using a simplified medication
adherence questionnaire (SMAQ), an indirect method
that has been validated in patients with HIV [22]. The
SMAQ consists of six questions that assess different
kinds of patient drug adherence:
a) Do you ever forget to take your medicine?
b) Are you careless at times about taking your medicine?
c) Sometimes if you feel worse, do you stop taking
your medicines?
d) Thinking about the last week. How often have you
not taken your medicine?
e) Did you not take any of your medicine over the past
weekend?
f ) Over the past 3 months, how many days have you
not taken any medicine at all?
Patients were classified as non-adherent if they replied
to any of the questions with a non-adherence answer.
For quantification of omissions, patients were classified
as non-adherent if they lost more than two doses during
the previous week or had not taken medication for more
than 2 complete days during the previous 3 months.
Patients who were classified as non-adherent were ex-
cluded from the study.
To minimize potential biases, all blood samples were
handled in the same manner and analysis was performed
by the same certified laboratory using validated techniques.
The ARV drugs, with their respective quality assurance cer-
tifications, were provided by Humax Pharmaceutical S.A.
Statistical analysis
Statistical analyses were performed using STATA/IC
13.1 (Stata Corp LP, College Station, Texas, USA). An
exploratory data analysis was used to calculate the central
tendency measures, dispersion, frequency tables, 95 % con-
fidence intervals, and normality tests. Data were reported
as percentages or medians [quartile 1 (Q1)–quartile (Q3)].
Wilcoxon matched-pairs signed-rank test was used to com-
pare proportions or medians. Comparisons were analyzed
using two-tailed tests, and p < 0.05 was considered statisti-
cally significant.
The primary analysis was the proportion of patients
who viral load <40 copies/mL at 12 months after base-
line to assess effectiveness. Both intention to treat (ITT)
analyses (consider all the subjects included at the beginning
of the study) and on treatment (OT) analyses (consider only
the subjects who fulfill completed the 12 months of
followed) were used to analyze the results.
Ethical approval
The study was conducted according to the ethical
principles regarding human experimentation established
in Colombia by both Resolutions 8430 of 1993 and 2378
of 2008, as the “Declaration of Helsinki” and its amend-
ments, and the Guide to Good Clinical Practice (ICH E6).
Informed consent was obtained from each participant
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before inclusion in the study. The study was approved by
the medical ethical committee from the institution partici-
pating (Comité de Ética para Investigación en Humanos de
la Corporación de Lucha Contra el SIDA–IRB 00005732at
U.S. Department of Health and Human Services).
Results
A flowchart of the patients involved in the Cali-Colombia
generic drug study is shown in Fig. 1. A group of 60 pa-
tients were invited to participate in the study; 42 were
enrolled and 33 completed the 12 months of follow-up.
Nine of the 42 patients presented reasons for excluding
from the study (Fig. 1). The demographic characteristics
of the 42 patients enrolled and 33 that completed the
study are shown in Table 1. In patients who completed
the study, the median age (Q1–Q3) was 37.0 (26.7–42.7)
years; 21 (63.6 %) were male, 24 (72.7 %) were employed,
and 27 (81.8 %) were identified as stage A (asymptomatic,
acute HIV, or persistent generalized lymphadenopathy),
according to the Centers for Disease Control and Preven-
tion [23].
Effectiveness of generic version of abacavir/lamivudine
and efavirenz
Regarding effectiveness at 12 months, 31 of 42 pa-
tients—73.8 % in intention-to-treat analysis; and 31 of
33 patients—93.9 % on-treatment analysis—achieved a
viral load of HIV1 RNA <40 copies/mL (Table 2). Between
baseline and 12 months, there were significantly increases
of 172 in the median (Q1–Q3) of CD4 T lymphocyte count
[373 (326–483) cells/mm3 vs. 545 (439–634) cells/mm3,
(p <0.001)], and of 12.9 % in median (Q1–Q3) of %CD4
[26.7 (20.0–32.7) vs. 39.6 (34–47), (p <0.001)]. Simi-
larly, there was a statistically significant increase in the
CD4 T-lymphocyte count/CD8 T-lymphocyte count
ratio above 0.5.
Safety of generic version of abacavir/lamivudine and
efavirenz
During 12 months of follow-up no meaningful or signifi-
cant changes were seen in renal, hepatic, and hematologic
function in the patients included and that completed the
study (Table 3). In addition, of the 42 patients included in
Fig. 1 Flow chart of patients invited to participate in the generic drug study, Cali-Colombia, 2011–2012
Galindo et al. BMC Infectious Diseases  (2016) 16:532 Page 5 of 13
the study, 9 (21.4 %) presented reasons for excluded from
the study. While no CV events were observed, one cART-
related adverse event leading to withdraw in one patient
(2.4 %) was due to increased CV risk (increased levels of
cholesterol, triglycerides, and hs-CRP). Exclusion of
the other eight patients from the study was owing to:
dropouts not associated with ARV therapy, four pa-
tients (9.5 %) and non-adherence to ARV drugs not
associated with safety problems, four patients (9.5 %),
identified during the initial 3 months of follow-up
(Fig. 1). Thus, among the 42 patients included in the
study, and the 37 adverse events considered related to
the study, cART was the cause of withdrawal in only
one case. The most frequently reported adverse events
were dizziness (7 patients), skin rash (6 patients), and
drowsiness (5 patients) (Table 4). Abacavir was not
associated with immunologically mediated hypersensi-
tivity reaction, thus patients did not presented with
this kind of adverse effect.
Lipids and cardiovascular risk
Patients included in the study showed significant increases
in TC, low-density lipoprotein cholesterol (LDL-C),
HDL-C, and triglycerides. There was a significant in-
crease of 2 %, in the median of the percentage of CV
risk score, according to the Framingham equation
(from −1 % to 1 %); however, at 48 weeks the CV risk
score for 33 patients continued to be valued as lower
risk, and only 1 patient was assessed as 10 % of CV risk
(Table 3).
Discussion
The current study describe the effectiveness and safety
ABC/3TC and EFV generic version for the treatment of
HIV/AIDS under the real-world clinical setting of a Cali,
Colombia medical practice. The findings showed that in
treatment-naïve HIV-infected patients 18 years or older
with indication to receive cART, without primary or
transmitted resistances, attending a program that pro-
vides comprehensive consultation and continuing care,
generic ABC/3TC and EFV was effective and safe as
Table 1 Demographic characteristics of patients (enrolled n = 42,
or completed the study n = 33), Cali-Colombia, 2011–2012
Patient characteristics n = 42 n = 33
Age, Median (Q1-Q3) Total 34.0 (24–43) 37.0 (26.7–42.7)
Men 30.0 (24.0–41.0) 37.0 (26.9–42.4)
Women 34.5 (26.0–44.0) 35.6 (24.6–44.9)
Gender, n (%) Male 28 (66.7) 21 (63.6)
Female 14 (33.3) 12 (36.4)
Ethnicity, n (%) Black 7 (16.7) 6 (18.2)
Nonblack 35 (83.3) 27 (81.8)
Marital status, n (%) Married 13 (31.0) 12 (36.4)
Single 29(69.0) 21 (63.6)
Education, n (%) Elementary 10 (23.8) 8 (24.2)
High school 17 (40.5) 13 (39.4)
Technical
education
6 (14.3) 5 (15.2)
University 9 (21.4) 7 (21.2)
Occupation, n (%) Home 5 (11.9) 4 (12.1)
Student 6 (14.3) 3 (9.1)
Unemployed 3 (7.1) 2 (6.1)




A 35 (83.3) 27 (81.8)
B 6 (14.3) 5 (15.2)
C 1 (2.4) 1 (3.0)
Q quartile
Table 2 Clinical variables related to drug effectiveness assessment, (enrolled n = 42, or completed the study n = 33), Cali-Colombia,
2011–2012
Clinical variable Baseline 3 months 6 months 12 months
Viral load copies/mL n = 42 n = 33 n = 33 n = 33 n = 33
Median (Q1–Q3) 18,013 (8236–44,936) 16,976 (7181–34,505) 0 (0-0) 0 (0-0) 0 (0-0)
≤40 copies, n (%)a 0 (0.0) 0 (0.0) 28 (84.8) 31 (93.9) 31 (93.9)
41-400 copies, n (%) 0 (0.0) 0 (0.0) 5 (15.2) 2 (6.1) 2 (6.1)
401-1.000 copies, n (%) 1 (2.4) 1 (3.0) 0 (0.0) 0 (0.0) 0 (0.0)
1.001-100.000 copies, n (%) 41 (97.6) 32 (97.0) 0 (0.0) 0 (0.0) 0 (0.0)
CD4 lymphocyte count (cell/mm3)
≥ 200 n (%) 39 (92.9) 31 (95.9) 33 (100.0) 33 (100.0) 33 (100.0)
Median (Q1–Q3)a 373 (326–483) 375 (333–491) 532 (426–587) 509 (390–558) 545 (439–634)
%CD4 lymphocyte
Median (Q1–Q3)a 26.7 (20.0–32.7) 26.7 (23.2–32.4) 34.6 (27.0–37.7) 37.6 (30.6–40.3) 39.6 (34–47)
Q quartile
ap-value <0.0011, for differences between baseline and 3, 6, and 12 months
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Table 3 Clinical variables related to drug safety assessment of patients (enrolled n = 42, or completed the study n = 33), Cali-Colombia,
2011–2012
Baseline 6 months 12 months p valuea
Clinical variable n = 42 n = 33 n = 33 n = 33
Transaminase (ALT) U/L
Median (Q1–Q3) 23 (18–32) 23.0 (17–32) 26.0 (18–41) 30.0 (20–44) 0.0452
Transaminase (AST) U/L
Median (Q1–Q3) 22 (19–34) 22.0 (20–36) 25.0 (20–29) 26.0 (20–32) 0.8792
Serum creatinine (mg/dL)
Median (Q1–Q3) 1.04 (0.97–1.17) 1.05 (0.98–1.17) 0.97 (0.90–1.06) 0.98 (0.90–1.09) 0.0895
Hemoglobin (g/dL)
Median (Q1–Q3) 14.9 (13.1–15.8) 14.4 (12.9–15.5) 14.7 (13.5–15.2) 14.6 (13.4–15.8) 0.1983
Fasting total cholesterol (mg/dL)
Median (Q1–Q3) 161.0 (140.0–177.0) 164.0 (140–179) 212.0 (191–231) 226.0 (200–246) <0.001
≤ 200, n (%) 39 (92.9) 30 (90.9) 13 (39.4) 9 (27.3) <0.001
200–240, n (%) 2 (4.8) 2 (6.1) 15 (45.4) 14 (42.4)
> 240, n (%) 1 (2.4) 1 (3.0) 5 (15.2) 10 (30.3)
Low-density lipoprotein cholesterol
–[LDL-C]– (mg/dL)
Median (Q1–Q3) 99.8 (87.4–114.9) 97.3 (87.4–114.9) 132.2 (116.1–152.3) 136.6 (115.3–155.1) <0.001
≤ 130, n (%) 37 (88.1) 29 (87.9) 16 (48.5) 13 (39.4) <0.001
130–160, n (%) 5 (11.9) 4 (12.1) 11 (33.3) 13 (39.4)
> 160, n (%) 0 (0.0) 0 (0.0) 6 (8.2) 7 (21.2)
High-density lipoprotein cholesterol –[HDL-C]– (mg/dL)
Median (Q1–Q3) 38.4 (32.7–44.5) 38.4 (33.4–46.1) 47.0 (38.6–56.6) 51.7 (42.8–60.3) <0.001
< 40for men or <50 for women, n (%) 27 (64.3) 18 (54.6) 9 (27.3) 6 (18.1) 0.0005
≥ 40 for men or ≥50 for women, n (%) 15 (35.7) 15 (45.4) 24 (72.3) 27 (81.8)
Total cholesterol/ HDL-cholesterol
Median (Q1–Q3) 4.2 (3.7–5) 4.0 (3.7–4.9) 4.4 (3.8–5.0) 4.3 (3.5–5.1) 0.2348
< 5, n (%) 32 (76.2) 25 (75.8) 25 (75.8) 25 (75.8)
≥ 5, n (%) 10 (23.8) 8 (24.2) 8 (24.2) 8 (24.2)
Triglycerides (mg/dL)
Median (Q1–Q3) 91 (76–126) 95 (76–126) 139 (99–179) 146 (105–208) <0.001
< 200, n (%) 40 (95.2) 32 (97.0) 27 (81.8) 24 (72.7) 0.0047
≥ 200, n (%) 2 (4.8) 1 (3.0) 6 (18.2) 9 (27.3)
High-sensitivity C-reactive protein (mg/L)
Median (Q1–Q3) 1.6 (1.1–3.4) 1.8 (1.2–3.4) 2.6 (1.1–4.5) 2.3 (1–5.1) 0.0635
Glycemia (mg/L)
Median (Q1–Q3) 88 (82–94) 88 (81–95) 89 (86–95) 91 (85–97) 0.0106
Waist circumference (cm)
Median (interquartile range) 85 (77–91) 85 (77–91) 84 (78–89) 84 (76–90) 0.6888
Cardiovascular risk according to Framingham score
Median (Q1–Q3) −1 (−1-1) −1 (−1-1) 1 (−1–2) 1 (−1–3) 0.0002
< 1, n (%) 26 (63.4) 20 (60.6) 14 (42.4) 16 (48.5) 0.0002
1, n (%) 9 (21.9) 8 (24.2) 9 (27 .3) 5 (15.2)
2, n (%) 4 (9.8) 3 (9.1) 5 (15.2) 3 (9.1)
3, n (%) 1 (2.4) 1(3.0) 1 (3.0) 3 (9.1)
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expected based on the proprietary drug scheme. The
findings are similar to those reported in a study designed
to assess the safety and effectiveness data from the
generic drug scheme lamivudine/zidovudine and efavirenz
in HIV/AIDS treatment naïve patients [14]. So, in another
study assessed the long-term safety, effectiveness, and
quality of the generic fixed-dose combination of nevira-
pine, stavudine and lamivudine [24]. These types of studies
will continue to assist generic drug companies in bringing
to market effective and safe ARV drugs, as information be-
comes available regarding the effectiveness and safety of
approved drugs.
Table 3 Clinical variables related to drug safety assessment of patients (enrolled n = 42, or completed the study n = 33), Cali-Colombia,
2011–2012 (Continued)
4, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.0)
5, n (%) 0 (0.0) 0 (0.0) 1 (3.0) 2 (6.1)
6, n (%) 1 (2.4) 1 (3.0) 3 (9.1) 1 (3.0)
8, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.0)
10, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.0)
Q quartile
aFor differences between baseline and 12 months
Table 4 Adverse events observed in patients treated with generic abacavir/lamivudine and efavirenz in comparison to adverse
events reported in published clinical trials evaluating the same branded drugs










Skin rash, n (%) 6 (14.3) 7 (7.2) 21 (6.5) 16 (9.6)
Dizziness, n (%) 7 (16.7) No reported 18 (5.6) 9 (5.4)
Drowsiness, n (%) 5 (11.9) No reported No reported No reported
Depressive disorder, n (%) 3 (7.1) No reported 20 (6.2) 8 (4.8)
Sleep disorder (insomnia), n (%) 3 (7.1) 8 (8.2) 20 (6.2) 10 (5.9)
Dreams, n (%) 2 (4.8) 6 (6.2) 15 (4.6) No reported
Anxiety, n (%) 1 (2.4) No reported No reported 4 (2.4)
Tingling/Numbness (Sensation of heat) 3 (7. 1) No reported No reported No reported
Dyspepsia or abdominal pain, n (%) 3 (7.1) No reported 12 (3.7) No reported
Nausea, n (%) 1 (2.4) 4 (4.1) 22 (6.8) No reported
Anorexia 1 (2.4) No reported No reported No reported
Fatigue/weakness, n (%) 1 (2.4) 1 (2.4) No reported 7 (4.2)
Increased cardiovascular risk - leading to
study drug discontinuation
1 (2.4) No reported No reported No reported
Vomiting, n (%) 0 (0.0) No reported 7 (2.2) No reported
Suspected hypersensitivity to abacavir
or other drug, n (%)
0 (0.0) 8 (8.2) 28 (8.6) 17 (10.1)
Headache, n (%) 0 (0.0) No reported 19 (5.9) 10 (5.9)
Ear, nose, and throat (ENT) Infections, n (%) 0 (0.0) No reported 29 (9.0) 11 (6.6)
Upper respiratory tract infection, n (%) 0 (0.0) No reported 13 (4.0) 9 (5.4)
Diarrhea, n (%) 0 (0.0) 1 (1.0) 22 (6.8) 6 (3.6)
Viral respiratory infection, n (%) 0 (0.0) No reported 21 (6.5) No reported
Musculoskeletal pain, n (%) 0 (0.0) No reported 21 (6.5) No reported
Hypertriglyceridemia, n (% among 33
finished the study)
8 (24.2) 9 (9.3) 18 (5.6) No reported
Increased Creatinine phosphokinase, n (%) No assessed No reported No reported 19 (11.4)
Increased liver function test results, n (%) 0 (0.0) No reported 13 (4.0) 14 (8.4 %)
Anemia, n (%) 0 (0.0) No reported 7 (2.2) No reported
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Effectiveness
Ideally, it would be to compare the change form baseline
CD4 cells/mm3 and HIV RNA copies/mL with another
arm or a less with results obtained in a group with similar
conditions [14]. Thus, we conducted a review in PubMed/
Medline to identify articles with clinical results in patients
with HIV/AIDS in treatment with ABC/3TC and EFV ori-
ginal drugs. Search terms were: abacavir/lamivudine and
efavirenz. Thus, we identified the main articles with results
associate to use the scheme ABC/3TC and efavirenz, in-
cluding the published generate from AIDS Clinical Trials
Group A5202 [25–27]. However, both significant difference
in baseline CD4 cells/mm3 as in values of HIV RNA cop-
ies/mL in our study limited to use these results as a possible
indirect comparator arm [14]. For instance in the Study
A5202 [26], in the abacavir/lamivudine and efavirenz arm
(n = 465), both the baseline median CD4 count (Q1–Q3)
[225 (103–324) cells/mm3] and the baseline median HIV-1
RNA level (Q1–Q3), [4.7 (4.3–5.0) log10 copies/mL] differ-
ent notorious from our baseline values median CD4 count
(Q1–Q3) [373 (326–483) cells/mm3] and median HIV-1
RNA level (Q1–Q3) [(4.3 (3.9–4.7) log10 copies/mL].
Currently, it is expected that initial cART has a virologic
response rate higher than 90 % at 12 months [28]. In this
study 74 % of patients (intention-to-treat analysis) in treat-
ment with ABC/3TC and EFV obtained undetectable viral
load, a value similar to those reported in other studies
(75 % [29], 72 % [30], and 71 % [31]) of patients in treat-
ment with this ARV scheme; but it was higher than 64 %
[32], and 57 % [33] reported in other studies (Table 5).
There was a significant increase (172 cells/mm3) in the me-
dian for CD4 T lymphocyte count (Tables 2 and 5), a value
that was closer to those reported for several studies in
which the increases in the median for CD4 T lymphocyte
count ranged between 130 and 209 cells/mm3 (Table 5).
Safety
The most frequently identified adverse events related to
ARV drugs in the 42 patients were dizziness (16.7 %),
skin rash (14.3 %), and drowsiness (11.9 %) (Table 4).
ABC was not associated with immunologically mediated
hypersensitivity reaction. During the 12 months of
follow-up, there were no significantly changes in renal,
hepatic, or hematologic function among the 33 patients
who completed the study (Table 3). The safety profile of
the generic version of ABC/3TC and EFV (Tables 3 and 4)
was similar to that reported for the proprietary ARV drugs
(during 12 months of follow-up), especially with the in-
crease of TC, LDL-C, HDL-C, and the CV risk. However,
the frequency of some types of adverse events such as skin
rash, dizziness, and hypertriglyceridemia was higher com-
pared with other studies (Tables 3 and 4). This difference
could be explained by closer and continuing follow-up of
patients by the pharmacist and the smaller number of
patients in the study.
It is important to note that of the 42 patients included
in the study, only one experienced a cART-related adverse
event leading to withdrawn, specifically due to increased
CV risk. The other eight causes for excluding were for rea-
sons not associated with ARV therapy (four patients) and
non-adherence to ARV drugs (four patients) did no drug-
related treatment. A total of 37 adverse events considered
related to the study were reported for the 42 patients but
cART only was the cause of withdrawal for just one patient,
2.4 % (1 of 42). Compared with other studies that used
ABC/3TC and EFV proprietary scheme, this value is lower
than 4.9 % (16 of 324 patients) [30], 10.7 % (18 of 169 pa-
tients) [31], 13.0 % (25 of 192 patients) [32], and 22.2 % (14
of 63 patients; 6 discontinued due to a hypersensitivity reac-
tion/rash) [33]. These differences could be caused by drug
hypersensitivity, including ABC hypersensitivity reaction,
mainly in studies where HLA-B*5701 (or HLA-B*57) geno-
type test was not screening at baseline [30, 31, 33]. In our
study neither patient presented ABC hypersensitivity reac-
tion. This was expected because the patients received gen-
etic screened for the HLA-B*57 allele, an intervention that
would decrease the incidence of this adverse event. Patients
who test negative with HLA-B*57 screening comprise 90–
95 % of HIV-1-infected patients and require no further
HLA-B*5701 confirmation by molecular HLA method [34].
HLA-B*57 screening is a low-cost alternative to high-
resolution typing of patients, and lends itself to point-of-
care diagnostics and rapid assessment of low-risk patients
who can begin immediate therapy with ABC [35].
Both ABC/3TC [32, 36] and EFV [37, 38] may lead to
modest rises in TC, LDL-C, HDL-C, and triglycerides.
Our study showed statistically significant increases in
medians of 65.0 mg/dL in TC, of 36.8 mg/dL in LDL-C,
of 13.3 mg/dL in HDL-C, and of 55.0 mg/dL in triglycerides
(Table 3). Except for triglycerides, these increases were
similar to those reported in other studies. For instance, in
the Lake study there were significant increases of 48 mg/dL
in TC, and of 10 mg/dL in HDL-C [33]. In another study
with 75 patients, over 96 weeks there was an increase of
42.0 mg/dL in TC, of 21.6 mg/dL in LDL-C, of 25 mg/dL
in triglycerides, and of 18 mg/dL in HDL-C [39]. However,
these rises in cholesterol and triglycerides are not of suffi-
cient magnitude to influence CV risk. For example, in our
study the median of percentage of CV risk based on the
Framingham Equation [20] at baseline versus 48 weeks of
follow-up showed an increase of only 2 % (from −1 % to
1 %); thus, at 48 weeks, in the 33 patients, CV risk con-
tinued to be low (Table 3). Similarly, in the TOKEN study
(n = 178 patients at baseline) [40] there was an increase of
0.9 % in CV risk (baseline vs. 48 weeks, from 2.6 to 3.5 %).
The increase in the CV risk may be proportional to the
increase in TC levels, LDL-C, and triglycerides. However,
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Table 5 Effectiveness of abacavir/lamivudine and efavirenz (viral load non-detectable and increase in median of CD4) in HIV naive patients 18 years or older, compared with six
other HIV/AIDS drug treatment studies




Intention-to-treat analysis On-treatment analysis
Nonrandomized, open-label, phase IV study
(Current Study, viral load <40 copies/mL))
42 73.8 93.9 172 HLA-B*57 allele negative. 91.2 % patients with
viral load <40 copies/mL, in intention-to-treat
analysis; Failure
Open-label, multicenter, randomized trial of
up to 3 consecutive treatment regimens over
96 weeks in 291 subjects received abacavir/
lamivudine and efavirenz, ritonavir-boosted
amprenavir, or stavudine (CLASS Study) [29]
291 75 (estimated values from
figure 3C at 48 week)
91 (64 of 70 patients received
abacavir/lamivudine and efavirenz)
194 HLA-B*5701 genotype test was not screening.
Results included patients with viral
load <100.000 or > 100.000 copies/mL
Multicenter, randomized, double-blind no
inferiority clinical trial of abacavir with
zidovudine plus lamivudine and efavirenz
(CNA30024 Study) [30]
324 71.7 (142 of 198 patients
with viral load <100.000
copies/mL)
89.3 % (226 of 253 patients with
viral load <100.000 or > 100.000
copies/mL)
209 HLA-B*5701 genotype test was not screening.
Randomized, open-label, multicenter study
of abacavir/lamivudine administered with
tenofovir or efavirenz (ESS30009 Study) [31]
169 71.0 94.5 130 HLA-B*5701 genotype test was not screening.
The majority of subjects in the tenofovir arm
switched regimens or withdrew before week 16
Multicenter, randomized, open-label study
of abacavir/lamivudine or tenofovir/emtricitabine
administered with efavirenz (ASSERT Study) [32]
192 64.2 (61 of 95 patients with
viral load <100.000 copies/mL)
N/D 150 HLA-B*5701 genotype negative.
Viral load suppression as secondary efficacy
endpoints
Multicenter and randomized study of efavirenz
with abacavir/lamivudine or lopinavir/r with
abacavir/lamivudine (Lake Study) [33]
63 56.7 87.0 193 HLA-B*5701 genotype test was not screening.
Results included patients with viral
load <100.000 or > 100.000 copies/mL
Multicenter retrospective study of tenofovir-
emtricitabine or abacavir-lamivudine,
administered with efavirenz for 260 weeks
(TOKEN Study) [40]
75 N/D 85 135 HLA-B*5701 genotype negative.
Estimated values at 48 week from Fig. 1a (viral














ABC has been associated only to slight increase of the CV
risk, and more important the data related to ABC, as a
cause of myocardial infarction, remain inconclusive and
controversial. In this way, some studies have concluded
that an increased risk of myocardial infarction exists in pa-
tients exposed to ABC in the preceding 6 months [41]
and it has been associated with increase of the CV risk
[42]; however, myocardial infarction associated to ABC
has not been seen in randomized clinical trials or meta-
analysis [43, 44].
This study provides important elements for evaluation
regarding the effectiveness and safety of generic ARVs
produced in Colombia. Phase IV clinical trials could be
an important option to assess and support the quality of
generic drugs used in standardized clinical practice [14].
Our findings do not necessarily indicate therapeutic equiva-
lence between ABC/3TC and EFV generic and proprietary
ARV, but they do support the quality and use of this generic
version. In developing countries, including Colombia, to
guarantee the long-term sustainability of access to ART it is
necessary to develop and support the generic market [7, 8].
Efforts are need to reduce drug costs through increased
use of generic drugs, price negotiation, and public health
directives such as compulsory licensing [45]. Colombia is
considered as a country on resource and capacity limited
settings, and it is expected that the use of generics may im-
prove the coverage to ARV drugs [4]. Although bioequiva-
lence of ART regimen composed by ABC/3TC and EFV
generics have been determined according to Colombia reg-
ulations [13], the results of this study may contribute both
to generate trust in the quality of the generic drugs and to
improve the coverage to ARV drugs, due to increase of use
of generic ART manufactured in Colombia. In this way, it
is important to denote that the 9.7 million people receiving
ART in low- and middle-income countries, for instance
Colombia, represents only 34 % (32–37 %) of the 28.6
(26.5–30.9) million people eligible in 2013 [1].
Study limitations
Because our study had several limitations, the results and
conclusions should be interpreted with caution. First, this
study was based on a small sample of HIV/AIDS treatment
naïve patients who were followed for only 12 months. Thus,
the small sample size could be insufficient to obtain strong
conclusions. However, the current study may prove clinical
information about effectiveness and safety of ABC/3TC
and EFV generics, which has been considered as scarce
[11]. Second, it was a nonrandomized, open-label, study;
therefore it lacked a control group and causal effect could
not be established. It is important to note that we did not
find studies of patients in treatment with ABC/3TC and
EFV original drugs and with similar viral load and lympho-
cytes CD4 count at baseline. In our study patients start
cART with lower baseline viral load and upper lymphocytes
CD4 count, compared with other studies. In addition, we
have to use the results from studies in populations and end-
points different, which may generated some limitations.
However, these studies proved an overall of clinic results
obtained with scheme ABC/3TC and EFV original drugs.
Finally, our study could be confounded by pharmaceutical
care performed by a pharmacist trained in this practice and
using the DADER method, oriented service mainly to mon-
itoring drug outcomes, and counseling regarding adherence
and appropriate use of ARV drugs by patients [17, 21], con-
ditions that are critical in the first 3 months and may have
improved clinical outcomes.
Conclusions
In a small group of HIV-infected treatment naïve patients
followed for 12 months, this open-label, nonrandomized
study showed that, as expected, the clinical outcomes of
generic drug version of ABC/3TC and EFV were com-
patible with the safety and effectiveness profile of pro-
prietary ARV drugs.
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